Analysis of the risk of solid tumor following Hodgkin's disease

Haematologica

Volumn 82, Issue 1, 1997, Pages 57-63

  Enrici, Riccardo Maurizi ^a   Anselmo, Anna Paola ^b   Osti, Mattia Falchetto ^b   Santoro, Mariaquila ^b   Tombolini, Vincenzo ^b   Mandelli, Franco ^b   Biagini, Carissimo ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chemotherapy; Hodgkin's disease; Radiotherapy; Risk factors; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; SOLID TUMOR; SPLENECTOMY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GLYOXAL; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; ITALY; MALE; MECHLORETHAMINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; RADIOTHERAPY; RISK; SPLEEN; SPLENECTOMY; SURVIVAL ANALYSIS; VINBLASTINE; VINCRISTINE;

EID: 0031451955     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Maurizi Enrici R, Anselmo AP, Osti MF, Sbarbati S, Tombolini V, Biagini C. Methods of assessment of delayed damage in patients treated for Hodgkin's disease. Minutes of the XX AIRB Congress, 29-30 Sept, 1993:152-70.
2. Young RC, Bookman MA, Longo DL. Late complications of Hodgkin's disease management. Natl Cancer Inst Monogr 1990; 10:55-60.
3. Boivin JF, Hutchinson GB, Lyden M, Godbold J, Chorosh J, Schottenfeld D. Second primary cancer following treatment for Hodgkin's disease. J Natl Cancer Inst 1984; 72:233-41.
4. Coleman CN, Kaplan HS, Cox R, Varghese A, Butterfield P, Rosenberg SA. Leukemias, non-Hodgkin's lymphomas and solid tumors in patients treated for Hodgkin's disease. Cancer Survey 1982; 1:733-44.
5. Abrahamsen JF, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993; 11:255-61.
6. Cimino G, Papa G, Tura S, et al. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol 1991; 9:432-7.
7. Tucker MA. Solid second cancers following Hodgkin's disease. Hematol Oncol Clin North Am 1993; 7:389-400.
8. Sont JK, Van Stiphout WAH, Noordijk EM, et al. Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Ann Haematol 1992; 65:213-8.
9. Rodriguez MA, Fuller LM, Zimmermann SO, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 1993; 4:125-31.
10. Van Leeuwen FE, Klokman WJ, Hagenbeck A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12:312-25.
11. Urba WJ, Longo DL. Hodgkin's disease. N Engl J Med 1992; 326:678-87.
12. Van Leeuwen FE, Somers R, Taal BG, et al. Increased risk of lung cancer, non-Hodgkin's lymphoma and leukemia following Hodgkin's disease. J Clin Oncol 1989; 7:1046-58.
13. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4:830-7.
14. Papa G, Mauro FR, Anselmo AP, et al. Acute leukemia in patients treated for Hodgkin's disease. Br J Haematol 1984; 58:43-52.
15. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 19:710-7.
16. Devereux S, Selassie G, Vaughan-Hudson G, Vaughan-Hudson B, Linch DC. Leukemia complicating treatment for Hodgkin's disease: the experience of the BNLI. Br Med J 1990; 301:1077-80.
17. Krikorian JB, Burke JS, Rosenberg SA, Kaplan HS. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med 1979; 300:452-8.
18. National Research Council. Committee on the biological effects of ionizing radiation. The effects on populations of exposure to low levels of ionizing radiation. Washington DC: National Academy Press, 1980.
19. Kohn HI, Fry MRJ. Radiation carcinogenesis. N Engl J Med 1984; 23:504-11.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-81.
21. Benedetti J, Yenu K, Young L. Life tables and survival functions. In: Dixon WJ, eds. BMDP statistical software, Berkeley: University of California Press, 1983. p. 557-75.
22. Valagussa P. Second neoplasm following treatment of Hodgkin's disease. Curr Opin Oncol 1993; 5:805-11.
23. Economopoulos T, Stathakis N, Alexopoulos C, et al. Second malignancies following treatment for Hodgkin's disease: a Greek experience. Haematologica 1994; 79:273-6.
24. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's disease. Ann Oncol 1992; 3 (suppl. 4):117-28.
25. Boivin JF, O'Brien K. Solid cancer risk after treatment of Hodgkin's disease. Cancer 1988; 61:2541-6.
26. Maurizi Enrici R, Anselmo AP, Osti MF, et al. Long-term results of treatment of childhood and adolescent Hodgkin's disease in 73 patients:the experience of the Departments of Radiology and Hematology of the University of Rome "La Sapienza". Haematologica 1996; 81:245-52.
27. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Br Med J 1992; 304:1137-43.
28. Doria R, Holford T, Farber L, Prosnitz LR, Cooper DL. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 1995; 13:2016-22.
29. Daley MO, Coleman CN, Fajardo LF. Splenic injury caused by therapeutic irradiation. Am J Surg Pathol 1981; 5:325-31.
30. Daley MO, Coleman CN, Kaplan HS. Radiation-induced splenic atrophy in patients with Hodgkin's disease and non-Hodgkin's lymphomas. N Engl J Med 1980; 302:215-7.
31. Coleman CN, McDougall IR, Daley MO, Ager P, Bush S, Kaplan HS. Functional hyposplenia after splenic irradiation for Hodgkin's disease. Ann Int Med 1982; 96:44-7.
32. Dietrich PY, Henry-Amar M, Cosset JM, Bodis S, Bosq J, Hayat M. Second primary cancer in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? Blood 1994; 84:1209-15.
33. Mellemkjoer L, Olsen JH, Linet MS, Linet AMS, Gridley G, McLaughlin JK. Cancer risk after splenectomy. Cancer 1995; 75:577-83.
34. Pearson HA, Johnston D, Smith KA, Touloukian RJ. The born-again spleen. Return of splenic function after splenectomy for trauma. N Engl J Med 1978; 298:1389-92.
35. Biti GP, Cellai E, Magrini SM, Papi MG, Ponticelli P, Boddi V. Second solid tumors and leukemia after treatment for Hodgkin's disease:an analysis of 1121 patients from a single institution. Int J Rad Oncol Biol Phys 1994; 29:25-31.
36. Kaldor JM, Day NE, Bell J, et al. Lung cancer following Hodgkin's disease: a case-control study. Int J Cancer 1992; 52:677-81.
37. Van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87:1530-7.
38. Land CE, Boice JD Jr, Shore RE, Norman JE, Tokunaga M. Breast cancer risk from low-dose exposures to ionizing radiation: results of parallel analysis of three exposed populations of women. J Natl Cancer Inst 1980; 65:353-76.
39. Modan B, Chetrit A, Alfandary E, Katz L. Increased risk of breast cancer after low-dose irradiation [letter]. Lancet 1989; 1:629.
40. Hildreth NG, Shore RE, Dvoretsky PM. The risk of breast cancer after irradiation on the thymus in infancy. N Engl J Med 1989; 321:1281-4.
41. Shore RE, Hildreth N, Woodard E, Dvoretsky P, Hempelmann L, Pasternack B. Breast cancer among women given X-ray therapy for acute post-partum mastitis. J Natl Cancer Inst 1986; 77:689-96.
42. Tokunaga M, Land CE, Yamamoto T, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat Res 1987; 112:243-72.
43. Miller AB, Howe GR, Sherman GJ, et al. Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 1989; 321:1285-9.
44. Yahalom J, Petrek JA, Biddinger PW, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 1992; 10:1674-81.
45. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993; 85:25-31.
46. Kaldor JM, Day NE, Band P, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international colloborative study among cancer registries. Int J Cancer 1987; 39:571-85.
47. IARC. Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Some anticancer and immunosoppressive drugs. Lyon, 1981; 2.
48. Zinzani PL, Gherlinzoni F, Piovaccari G, et al. Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin's disease patients. Haematologica 1996; 81:132-7
49. Frezza G, Barbieri E, Zinzani PL, Babini L, Tura S. Supradiaphragmatic early stage Hodgkin's disease: does mantle radiation therapy still have a role? Haematologica 1996; 81:138-42.